Industry News
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas characterized by EORTC analysis
Feb 12, 2014
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor. Read More
Unexpected cell hijack method in pancreatic cancer revealed by study
Feb 12, 2014
Pancreatic stellate cells, which normally aid tissue repair, unwittingly help pancreatic cancer grow and spread in a method of 'cell hijack' only seen before in brain and breast cancer, according to new research from Queen Mary University of London. Read More
Possible genetic markers found in breast cancer that spreads to the brain
Feb 12, 2014
The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first-of-its-kind study published in the scientific journal PLOS ONE. Read More
Fungal disease attacked by breast cancer drug
Feb 12, 2014
Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio®, the online open-access journal of the American Society for Microbiology (ASM. Read More
How blood cancer's growth fueled in acute myelogenous leukemia
Feb 12, 2014
Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease. Read More
For women with BRCA gene mutation, 'double mastectomy better'
Feb 12, 2014
Women with early-stage breast cancer who have a mutation in the BRCA gene are much less likely to die from the disease if they have a double mastectomy, compared with women who have the mutation and only have one breast removed. This is according to a study published in the BMJ.The research team, including Prof. Read More
Hope for development of drugs to stall the growth of K-Ras cancers, previously deemed impossible to treat
Feb 12, 2014
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies to thwart tumor growth. Read More
Control of nanomotors inside living cells
Feb 12, 2014
For the first time, a team of chemists and engineers at Penn State University have placed tiny synthetic motors inside live human cells, propelled them with ultrasonic waves and steered them magnetically. It's not exactly "Fantastic Voyage," but it's close. The nanomotors, which are rocket-shaped metal particles, move around inside the cells, spinning and battering against the cell membrane. Read More
After percutaneous coronary intervention, surprising trends in cause of long-term death
Feb 12, 2014
More people who have known coronary heart disease die from other causes - such as cancer, and lung and neurological diseases - than heart disease, compared with 20 years ago, according to a Mayo Clinic study published online in Circulation, an American Heart Association journal. Read More
Consensus guideline on margins for breast-conserving surgery with whole-breast irradiation issued by ASTRO and SSO
Feb 12, 2014
Guideline focused on reducing ipsilateral breast tumor recurrence in stages I and II invasive breast cancer The American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) are pleased to announce the publication of the consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Read More
Previous Page Next Page